Defining criteria for anti-mannan antibodies to protect against candidiasis.
Prevention of hematogenously disseminated candidiasis and mucocutaneous disease, including Candida vaginitis, through immunological approaches is appealing for the following reason. A long-acting and safe vaccine that protects against both serotypes of Candida albicans and other important species, such as C. tropicalis and C. glabrata, should significantly reduce the incidence of various forms of candidiasis by these etiologic agents. Through extensive experimentation on protective responses in experimental animals against Candida mannan components, others and we have evidence that antibodies specific for short-chain beta-linked oligomannosides are protective against candidiasis. Although the mechanism of protection against vaginal infection requires further investigation, experimentally the ability of antibody to rapidly deposit high amounts of complement factor C3 onto the yeast cell wall is requisite for enhancing resistance against disseminated candidiasis.
The Research Institute for Children and LSUHSC, Dept of Pediatrics and Dept of Microbiology, Children's Hospital, New Orleans, LA 70118, USA. jcutler@chnola-research.org
J E
JE
Cutler
D000818:Animals; D000908:Antibodies, Fungal / Q000097:blood / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002176:Candida albicans / Q000276:immunology / Q000378:metabolism; D002177:Candidiasis / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D002473:Cell Wall / Q000378:metabolism; D003176:Complement C3 / Q000378:metabolism; D005260:Female; D006801:Humans; D008351:Mannans / Q000276:immunology / Q000627:therapeutic use*
D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D003176:Complement C3; D008351:Mannans